维得利珠单抗与英夫利西单抗在皮下抗TNF治疗失败后溃疡性结肠炎中的疗效与安全性比较:多中心队列研究
该多中心回顾性队列纳入225例既往至少一种皮下抗TNF药物(阿达木单抗或戈利木单抗)失败的溃疡性结肠炎患者,比较英夫利西单抗(IFX)与维得利珠单抗(VDZ)的疗效。第14周临床缓解率VDZ组49%(35/71)高于IFX组26%(40/154),倾向性评分匹配后差异仍显著(OR 1.67,95%CI 1.08-2.56,P=0.02)。中位随访117周,VDZ组无停药生存及无UC相关事件生存均优于IFX组。
要点
- 皮下抗TNF失败后,VDZ第14周临床缓解率49%高于IFX的26%。
- 匹配后VDZ缓解优势仍显著(OR 1.67,95%CI 1.08-2.56)。
- VDZ无停药生存及无UC相关事件生存均优于IFX。
核心结论
- 皮下抗TNF药物治疗失败的UC患者,使用VDZ比IFX更可能获得临床缓解。
- 尽管IFX组病情显著更重,校正及亚组分析后差异仍存在,但需前瞻性头对头试验确认。
研究设计与样本
- 法国12个中心连续纳入的UC患者回顾性研究,共225例。
- 纳入标准为至少接受过一次阿达木单抗或戈利木单抗注射后开始IFX或VDZ治疗。
- 主要结局为第14周临床缓解、无治疗停药生存及无UC相关事件生存。
主要发现
- 第14周临床缓解:IFX组40/154(26%),VDZ组35/71(49%),P=0.001。
- 倾向性评分匹配后差异仍显著:OR 1.67,95%CI 1.08-2.56,P=0.02。
- 中位随访117周,无治疗停药生存第1年和第3年:IFX组50%和29%,VDZ组80%和55%,P<0.001。
- 无UC相关事件生存第1年和第3年:IFX组49%和27%,VDZ组74%和52%,P<0.01。
临床怎么用
- 对于既往皮下抗TNF药物失败的UC患者,选择VDZ可能较IFX有更高的短期临床缓解率。
- 需注意IFX组患者病情显著更重,临床决策应结合个体病情严重程度综合判断。
局限性
- 回顾性研究设计,存在处方习惯等混杂因素,IFX组病情显著更重。
- 结果需前瞻性研究及专门的头对头试验确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few data exist to help select a second biologic agent in patients with refractory ulcerative colitis (UC). AIM: To compare the efficacy of infliximab (IFX) and vedolizumab (VDZ) in UC patients who failed a first subcutaneous anti-tumor necrosing factor (TNF) agent. METHODS: Consecutive UC patients from 12 French centres starting IFX or VDZ after at least one injection of adalimumab or golimumab have been included in a retrospective study. Outcomes were clinical remission at week 14, survival without treatment discontinuation and survival without UC-related event. RESULTS: Among the 225 patients included, clinical remission at week 14 was achieved in 40/154 (26%) patients treated with IFX and in 35/71 (49%) treated with VDZ (P = 0.001). After a propensity score matching analysis, this difference remained significant (odds ratio: 1.67; 95% confidence interval: 1.08-2.56; P = 0.02). With a median follow-up of 117 weeks, survival rates without treatment discontinuation at years 1 and 3 were 50% and 29% with IFX, and 80% and 55% with VDZ, respectively (P < 0.001). Regarding survival without UC-related event, they were 49% and 27% with IFX, and 74% and 52% with VDZ (P < 0.01). CONCLUSION: After failure of a first subcutaneous anti-TNF agent, UC patients were more likely to achieve clinical remission with VDZ than those treated with IFX. Although due to prescription habits patients in the IFX group had a significantly more severe disease, these differences remained after adjustments and subgroup analyses. Such results have to be confirmed prospectively and warrant dedicated head-to-head trials.
引用
- Hupé M, Rivière P, Nancey S, et al. Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study. Aliment Pharmacol Ther. 2020. PMID: 32201971. doi:10.1111/apt.15680
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。